Developer docs
API playgroundTry for free, no card

Search company profiles

CJ Bioscience

Full company profile

uuid003lhcn

Namestring
CJ Bioscience
Legal namestring
씨제이바이오사이언스 주식회사
Company typeenum
Private
Founded yearint
2009
Descriptiontext

CJ Bioscience is a South Korean biotechnology company and subsidiary of CJ Group that develops AI-powered microbiome science solutions spanning drug discovery, biomarker identification, infectious disease diagnostics, and precision nutrition. Founded in 2009 and headquartered in Seoul, the company operates an integrated platform architecture centered on its proprietary Ez-Mx® AI platform, which leverages over 20 years of accumulated gut microbiome analysis data combined with proprietary databases — a 1.2M+ entry Genome Database, a 28,000+ entry Metagenome Database, a 3.8M+ entry Functional Reference Database, and 12,000+ preserved bacterial strains. The company claims the world's largest microbiome drug pipeline, with lead candidates CJRB-201 for inflammatory bowel disease (IBD) and CJRB-101 in multi-country clinical trials for immuno-oncology applications targeting solid tumors including lung and head/neck squamous cell carcinoma.

The company's commercial footprint spans three business lines: (1) B2B SaaS-based microbiome analysis services (EzBioCloud™ and EzBioCloud Pro) serving researchers across 150+ countries, with 67,288 registered users and 3.5M+ cumulative analyses performed; (2) B2B partnerships with pharmaceutical companies for companion diagnostics and drug development; and (3) consumer-facing gut health testing services (Gut Inside, Smile Gut) and a precision nutrition platform (MAC) distributed through medical institutions in South Korea. The recently announced precision nutrition integrated platform combines the patent-pending DIGEST gut simulation system, DIGEST-Flow dynamic monitoring, and machine learning-based response prediction, validated through a 186-participant clinical trial demonstrating reproducible microbiome changes in human subjects. The company also operates TrueBac™ ID, positioned as the world's first genome-based infectious disease diagnostic service.

CJ Bioscience operates as a private subsidiary under CJ CheilJedang's wellness business division, with no venture capital ownership signals identified in available materials. Revenue and detailed financial information are not publicly disclosed. The company maintains active R&D operations including conference participation at KMB 2026 and IHMC 2026, ongoing clinical trials for drug candidates, and a planned H2 2026 commercial launch of a customized MAC precision nutrition solution. The company employs 51-100 staff and is led by founder & CEO Jon Chun.

Short descriptiontext

CJ Bioscience is a South Korean AI-powered microbiome science company developing drug candidates (CJRB-201 for IBD, CJRB-101 for solid tumors), SaaS bioinformatics platforms (EzBioCloud), and precision nutrition solutions serving pharmaceutical companies, research institutions, and consumers globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
microbiome therapeutics, bioinformatics analysis, gut health diagnostics, genomic sequencing services, precision nutrition platform
Industry5 codes
PRIMARYHLAAAFAI
Microbiome Analytics, Sequencing & Bioinformatics Platforms
SECONDARYHLAAAFAH
Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal)
SECONDARYHLAAAFAK
Microbiome Clinical Development & Translational Services (trial design, endpoints, sampling)
SECONDARYHLAGANAH
Microbiome & Metagenomics Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
NAICS code3 codes
  • Medical and Diagnostic Laboratories6215
  • Medical Laboratories621511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Microbiome Bioinformatics & Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B and B2C
B2B and B2C
Offering typeSoftware
Software
Brand1 of 9 records shown
1Ez-Mx
Description

AI-based precision analysis platform for disease prevention, diagnosis, and treatment across the healthcare spectrum.

cjbioscience.com:443
+8 more records
Core offering1 text field

CJ Bioscience develops and commercializes AI-powered microbiome science solutions, including the Ez-Mx® analysis platform, the EzBioCloud™ SaaS bioinformatics service, the TrueBac™ ID genome-based infectious disease diagnostic, the MAC precision nutrition integrated platform, and consumer gut microbiome testing services (Gut Inside, Smile Gut). The company also maintains what it describes as the world's largest microbiome drug pipeline, with candidates CJRB-201 (IBD) and CJRB-101 (solid tumors) in multi-country clinical trials, supported by proprietary databases covering 1.2M+ Genome DB entries, 28,000+ Metagenome DB entries, and 3.8M+ Functional Reference DB entries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 3x higher species-level microbial identification accuracy compared to public databases
+2 more records
Product overview1 text field

CJ Bioscience offers a unified platform architecture centered on the Ez-Mx® AI-powered microbiome platform, complemented by multiple integrated products and services. The portfolio includes SaaS-based genomic analysis services (EzBioCloud™, EzBioCloud Pro), genome-based infectious disease diagnostics (TrueBac™ ID), consumer-facing gut health services (Gut Inside, Smile Gut), the precision nutrition MAC platform, and a pipeline of microbiome-based drug candidates (CJRB-101, CJRB-201) targeting oncology and inflammatory bowel disease. The ecosystem is built on proprietary databases including 1.2M+ Genome DB, 28,000+ Metagenome DB, 3.8M+ Functional Reference DB, and 12,000+ bacterial strains, supporting analysis across 150+ countries.

Product and service10 records
1Ez-Mx® Platform
CategoryMicrobiome analysis platform
Description

AI-powered precision analysis platform that supports disease prevention, diagnosis, and treatment workflows, integrating genomic analysis, biomarker discovery, and companion diagnostics to accelerate pharmaceutical drug development. Targeted at pharmaceutical R&D and precision medicine programs.

2EzBioCloud™
CategoryBioinformatics SaaS
Description

SaaS-based bioinformatics analysis service for microbial identification and microbiome genomic analysis, used by researchers worldwide. Powered by CJ Bioscience's proprietary microbial genome database, it is positioned as a global standard bioinformatics service for the microbiome research community.

3TrueBac™ ID
CategoryInfectious disease diagnostics
Description

Genome-based infectious disease diagnosis service that rapidly identifies unknown pathogens to guide optimal treatment methods. Designed for clinical and research laboratories requiring rapid, accurate infectious disease diagnostics.

4Gut Inside
CategoryConsumer gut microbiome testing
Description

Adult-targeted intestinal microorganism examination service distributed through specialized medical institutions for gut microbiome health assessment. Targeted at South Korean consumers seeking clinically-supervised gut microbiome testing.

5Smile Gut
CategoryConsumer gut microbiome testing
Description

Consumer-focused digital service for personalized gut health management through individual gut microorganism analysis. Targeted at consumers managing gut wellness digitally outside the medical-institution channel.

6MAC (My Alimentary Code)
CategoryPrecision nutrition platform
Description

Precision nutrition integrated platform connecting analysis, gut simulation (DIGEST), clinical evidence, and AI-based response prediction for full-cycle verification of nutritional intervention efficacy. Targeted at nutrition, wellness, and consumer health applications, with planned customization as individual MAC solutions.

7CJRB-201
CategoryMicrobiome drug pipeline candidate
Description

Microbiome-based drug candidate for Inflammatory Bowel Disease (IBD) treatment that colonizes the gut to produce butyrate and active metabolites, connecting to Treg induction and mucosal barrier recovery mechanisms. Targeted at pharmaceutical partners and eventually patients with IBD.

8CJRB-101
CategoryMicrobiome drug pipeline candidate
Description

Microbiome-based drug candidate targeting solid tumors including lung cancer and head and neck squamous cell carcinoma, advancing through multi-country clinical trials for Immuno-Oncology applications. Targeted at oncology patients and pharmaceutical partners in immuno-oncology.

9NGS Service
CategorySequencing and bioinformatics service
Description

Next Generation Sequencing-based microbiome genome analysis service using highest-level NGS and bioinformatics technology to provide total bioinformatics solutions in the microbial field. Targeted at research institutions and pharmaceutical clients requiring outsourced sequencing and analysis.

10BI Consulting Service
CategoryBioinformatics consulting
Description

Bioinformatics consulting service providing specialized analysis support for researchers and organizations. Targeted at clients needing custom microbiome study design, data analysis, and bioinformatics interpretation.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Personalized nutrition platform based on gut microbiome analysis, serving both consumers and B2B (including health plans and providers). Closely comparable on consumer microbiome-based precision nutrition business model.

TypeDirect peer
Description

Clinical-stage company developing defined bacterial consortia for recurrent C. difficile and IBD, with a major partnership with Janssen. Comparable on microbiome-defined therapeutics and IBD pipeline overlap.

TypeDirect peer
Description

European clinical-stage microbiome therapeutics company developing standardized gut microbiome therapies for oncology (GvHD) and IBD. Direct competitor in microbiome-based drug pipeline targeting similar indications.

TypeDirect peer
Description

Microbiome therapeutics company developing targeted microbial cocktails for IBD and recurrent C. difficile infection. Direct peer in defined-consortium microbiome drug development.

5Second Genome
TypeDirect peer
Description

Microbiome drug discovery company using proprietary bioinformatics and screening platform to identify microbial targets. Comparable on AI/bioinformatics-driven microbiome drug discovery approach.

TypeDirect peer
Description

Microbiome therapeutics pioneer (RBX2660 for recurrent C. difficile, now FDA-approved as Rebyota under Ferring). Most advanced microbiome therapeutic peer; comparable pipeline scope and clinical maturity.

TypeDirect peer
Description

Clinical-stage biotechnology company with a microbiome-focused drug discovery platform targeting IBD and other inflammatory diseases. Direct comparable in microbiome therapeutic pipeline and bioinformatics platform strategy.

TypeDirect peer
Description

US clinical-stage microbiome therapeutics company developing defined bacterial consortia for IBD (SER-109) and immuno-oncology. Most direct global peer given overlapping IBD drug development and microbiome therapeutic focus.

TypeDirect peer
Description

Clinical-stage Live Biotherapeutic company with pipeline candidates across oncology, IBD, and respiratory disease. Closely aligned microbiome therapeutics scope and multi-indication strategy.

TypeDirect peer
Description

Consumer-facing AI-driven microbiome testing and personalized nutrition company. Direct comparable on Gut Inside/Smile Gut consumer testing and precision nutrition offerings.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature10 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CJ Bioscience

Microbiome Bioinformatics & Therapeuticscjbioscience.com

CJ Bioscience is a South Korean AI-powered microbiome science company developing drug candidates (CJRB-201 for IBD, CJRB-101 for solid tumors), SaaS bioinformatics platforms (EzBioCloud), and precision nutrition solutions serving pharmaceutical companies, research institutions, and consumers globally.

What CJ Bioscience does

CJ Bioscience is a South Korean biotechnology company and subsidiary of CJ Group that develops AI-powered microbiome science solutions spanning drug discovery, biomarker identification, infectious disease diagnostics, and precision nutrition. Founded in 2009 and headquartered in Seoul, the company operates an integrated platform architecture centered on its proprietary Ez-Mx® AI platform, which leverages over 20 years of accumulated gut microbiome analysis data combined with proprietary databases — a 1.2M+ entry Genome Database, a 28,000+ entry Metagenome Database, a 3.8M+ entry Functional Reference Database, and 12,000+ preserved bacterial strains. The company claims the world's largest microbiome drug pipeline, with lead candidates CJRB-201 for inflammatory bowel disease (IBD) and CJRB-101 in multi-country clinical trials for immuno-oncology applications targeting solid tumors including lung and head/neck squamous cell carcinoma.

The company's commercial footprint spans three business lines: (1) B2B SaaS-based microbiome analysis services (EzBioCloud™ and EzBioCloud Pro) serving researchers across 150+ countries, with 67,288 registered users and 3.5M+ cumulative analyses performed; (2) B2B partnerships with pharmaceutical companies for companion diagnostics and drug development; and (3) consumer-facing gut health testing services (Gut Inside, Smile Gut) and a precision nutrition platform (MAC) distributed through medical institutions in South Korea. The recently announced precision nutrition integrated platform combines the patent-pending DIGEST gut simulation system, DIGEST-Flow dynamic monitoring, and machine learning-based response prediction, validated through a 186-participant clinical trial demonstrating reproducible microbiome changes in human subjects. The company also operates TrueBac™ ID, positioned as the world's first genome-based infectious disease diagnostic service.

CJ Bioscience operates as a private subsidiary under CJ CheilJedang's wellness business division, with no venture capital ownership signals identified in available materials. Revenue and detailed financial information are not publicly disclosed. The company maintains active R&D operations including conference participation at KMB 2026 and IHMC 2026, ongoing clinical trials for drug candidates, and a planned H2 2026 commercial launch of a customized MAC precision nutrition solution. The company employs 51-100 staff and is led by founder & CEO Jon Chun.

CJ Bioscience firmographics

Firmographics
Name
CJ Bioscience
Legal name
씨제이바이오사이언스 주식회사
Website
https://cjbioscience.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
51–100 employees
Short description
CJ Bioscience is a South Korean AI-powered microbiome science company developing drug candidates (CJRB-201 for IBD, CJRB-101 for solid tumors), SaaS bioinformatics platforms (EzBioCloud), and precision nutrition solutions serving pharmaceutical companies, research institutions, and consumers globally.
Ownership category
akta.pro rank

CJ Bioscience industry classification

Industry
Product category
Microbiome Bioinformatics & Therapeutics
NAICS
Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAAFAI
Microbiome Analytics, Sequencing & Bioinformatics Platforms
SECONDARYHLAAAFAH
Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal)
SECONDARYHLAAAFAK
Microbiome Clinical Development & Translational Services (trial design, endpoints, sampling)
SECONDARYHLAGANAH
Microbiome & Metagenomics Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories

Keywords

  • Microbiome therapeutics
  • Bioinformatics analysis
  • Gut health diagnostics
  • Genomic sequencing services
  • Precision nutrition platform

Where CJ Bioscience is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices1 record

Markets served

CJ Bioscience business model

Business model
GTM type
B2B and B2C
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

CJ Bioscience product offering

Product offering

Core offering

CJ Bioscience develops and commercializes AI-powered microbiome science solutions, including the Ez-Mx® analysis platform, the EzBioCloud™ SaaS bioinformatics service, the TrueBac™ ID genome-based infectious disease diagnostic, the MAC precision nutrition integrated platform, and consumer gut microbiome testing services (Gut Inside, Smile Gut). The company also maintains what it describes as the world's largest microbiome drug pipeline, with candidates CJRB-201 (IBD) and CJRB-101 (solid tumors) in multi-country clinical trials, supported by proprietary databases covering 1.2M+ Genome DB entries, 28,000+ Metagenome DB entries, and 3.8M+ Functional Reference DB entries.

Product overview

CJ Bioscience offers a unified platform architecture centered on the Ez-Mx® AI-powered microbiome platform, complemented by multiple integrated products and services. The portfolio includes SaaS-based genomic analysis services (EzBioCloud™, EzBioCloud Pro), genome-based infectious disease diagnostics (TrueBac™ ID), consumer-facing gut health services (Gut Inside, Smile Gut), the precision nutrition MAC platform, and a pipeline of microbiome-based drug candidates (CJRB-101, CJRB-201) targeting oncology and inflammatory bowel disease. The ecosystem is built on proprietary databases including 1.2M+ Genome DB, 28,000+ Metagenome DB, 3.8M+ Functional Reference DB, and 12,000+ bacterial strains, supporting analysis across 150+ countries.

Differentiator

Problem solved

Functional benefit

Brands

  • Ez-Mx: AI-based precision analysis platform for disease prevention, diagnosis, and treatment across the healthcare spectrum.
  • EzBioCloud
  • EzBioCloud Pro
  • TrueBac ID
  • Gut Inside
  • MAC
  • DIGEST
  • DIGEST-Flow
  • Smile Gut

Products and services

  • Ez-Mx® Platform AI-powered precision analysis platform that supports disease prevention, diagnosis, and treatment workflows, integrating genomic analysis, biomarker discovery, and companion diagnostics to accelerate pharmaceutical drug development. Targeted at pharmaceutical R&D and precision medicine programs.
  • EzBioCloud™ SaaS-based bioinformatics analysis service for microbial identification and microbiome genomic analysis, used by researchers worldwide. Powered by CJ Bioscience's proprietary microbial genome database, it is positioned as a global standard bioinformatics service for the microbiome research community.
  • TrueBac™ ID Genome-based infectious disease diagnosis service that rapidly identifies unknown pathogens to guide optimal treatment methods. Designed for clinical and research laboratories requiring rapid, accurate infectious disease diagnostics.
  • Gut Inside Adult-targeted intestinal microorganism examination service distributed through specialized medical institutions for gut microbiome health assessment. Targeted at South Korean consumers seeking clinically-supervised gut microbiome testing.
  • Smile Gut Consumer-focused digital service for personalized gut health management through individual gut microorganism analysis. Targeted at consumers managing gut wellness digitally outside the medical-institution channel.
  • MAC (My Alimentary Code) Precision nutrition integrated platform connecting analysis, gut simulation (DIGEST), clinical evidence, and AI-based response prediction for full-cycle verification of nutritional intervention efficacy. Targeted at nutrition, wellness, and consumer health applications, with planned customization as individual MAC solutions.
  • CJRB-201 Microbiome-based drug candidate for Inflammatory Bowel Disease (IBD) treatment that colonizes the gut to produce butyrate and active metabolites, connecting to Treg induction and mucosal barrier recovery mechanisms. Targeted at pharmaceutical partners and eventually patients with IBD.
  • CJRB-101 Microbiome-based drug candidate targeting solid tumors including lung cancer and head and neck squamous cell carcinoma, advancing through multi-country clinical trials for Immuno-Oncology applications. Targeted at oncology patients and pharmaceutical partners in immuno-oncology.
  • NGS Service Next Generation Sequencing-based microbiome genome analysis service using highest-level NGS and bioinformatics technology to provide total bioinformatics solutions in the microbial field. Targeted at research institutions and pharmaceutical clients requiring outsourced sequencing and analysis.
  • BI Consulting Service Bioinformatics consulting service providing specialized analysis support for researchers and organizations. Targeted at clients needing custom microbiome study design, data analysis, and bioinformatics interpretation.

Quantifiable outcome

  • 3x higher species-level microbial identification accuracy compared to public databases
  • +2 more outcomes

Companies that use CJ Bioscience

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

CJ Bioscience technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature10 records

CJ Bioscience partnerships and signals

Strategic signal

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

CJ Bioscience competitors and assessment

Company assessment

Direct peers

  • DayTwo: Personalized nutrition platform based on gut microbiome analysis, serving both consumers and B2B (including health plans and providers). Closely comparable on consumer microbiome-based precision nutrition business model.
  • Vedanta Biosciences: Clinical-stage company developing defined bacterial consortia for recurrent C. difficile and IBD, with a major partnership with Janssen. Comparable on microbiome-defined therapeutics and IBD pipeline overlap.
  • MaaT Pharma: European clinical-stage microbiome therapeutics company developing standardized gut microbiome therapies for oncology (GvHD) and IBD. Direct competitor in microbiome-based drug pipeline targeting similar indications.
  • Finch Therapeutics: Microbiome therapeutics company developing targeted microbial cocktails for IBD and recurrent C. difficile infection. Direct peer in defined-consortium microbiome drug development.
  • Second Genome: Microbiome drug discovery company using proprietary bioinformatics and screening platform to identify microbial targets. Comparable on AI/bioinformatics-driven microbiome drug discovery approach.
  • Rebiotix (Ferring Pharmaceuticals): Microbiome therapeutics pioneer (RBX2660 for recurrent C. difficile, now FDA-approved as Rebyota under Ferring). Most advanced microbiome therapeutic peer; comparable pipeline scope and clinical maturity.
  • Assembly Biosciences: Clinical-stage biotechnology company with a microbiome-focused drug discovery platform targeting IBD and other inflammatory diseases. Direct comparable in microbiome therapeutic pipeline and bioinformatics platform strategy.
  • Seres Therapeutics: US clinical-stage microbiome therapeutics company developing defined bacterial consortia for IBD (SER-109) and immuno-oncology. Most direct global peer given overlapping IBD drug development and microbiome therapeutic focus.
  • 4D Pharma: Clinical-stage Live Biotherapeutic company with pipeline candidates across oncology, IBD, and respiratory disease. Closely aligned microbiome therapeutics scope and multi-indication strategy.
  • Viome Life Sciences: Consumer-facing AI-driven microbiome testing and personalized nutrition company. Direct comparable on Gut Inside/Smile Gut consumer testing and precision nutrition offerings.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

CJ Bioscience social profiles

Digital presence

CJ Bioscience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CJ Bioscience leadership team

Management profile

Number of profiles

Profiles1 record

CJ Bioscience funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CJ Bioscience M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CJ Bioscience

What does CJ Bioscience do?

CJ Bioscience develops and commercializes AI-powered microbiome science solutions, including the Ez-Mx® analysis platform, the EzBioCloud™ SaaS bioinformatics service, the TrueBac™ ID genome-based infectious disease diagnostic, the MAC precision nutrition integrated platform, and consumer gut microbiome testing services (Gut Inside, Smile Gut). The company also maintains what it describes as the world's largest microbiome drug pipeline, with candidates CJRB-201 (IBD) and CJRB-101 (solid tumors) in multi-country clinical trials, supported by proprietary databases covering 1.2M+ Genome DB entries, 28,000+ Metagenome DB entries, and 3.8M+ Functional Reference DB entries.

Is CJ Bioscience a public or private company?

CJ Bioscience is a private company. It is classified as corporate owned and is currently operating.

When was CJ Bioscience founded?

CJ Bioscience was founded in 2009. It employs 51 to 100 people.

Where is CJ Bioscience based?

CJ Bioscience is headquartered in Seoul, South Korea, in the Asia region.

Who are CJ Bioscience's main competitors?

Direct peers on record are DayTwo, Vedanta Biosciences, MaaT Pharma, Finch Therapeutics, Second Genome, Rebiotix (Ferring Pharmaceuticals), Assembly Biosciences, Seres Therapeutics, 4D Pharma and Viome Life Sciences.

Does CJ Bioscience have an API?

No public API is recorded for CJ Bioscience.

What industry is CJ Bioscience in?

CJ Bioscience's product category is Microbiome Bioinformatics & Therapeutics. Its primary akta.pro industry code is HLAAAFAI, Microbiome Analytics, Sequencing & Bioinformatics Platforms, with a secondary code of HLAAAFAH, Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal). Its NAICS code is 6215 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales